ALPS Medical Breakthroughs ETF
SBIO
60 hedge funds and large institutions have $71.7M invested in ALPS Medical Breakthroughs ETF in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 10 closing their positions.
537% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $218K
2.71% more ownership
Funds ownership: 32.69% → 35.39% (+2.7%)
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
4% less capital invested
Capital invested by funds: $74.8M → $71.7M (-$3.15M)
9% less funds holding
Funds holding: 66 → 60 (-6)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$2.84M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.57M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.14M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$1.13M |
| 5 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.54M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.29M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.16M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$871K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$462K |
SBIO Hedge Fund Activity: Q3 2021 in Review
60 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ALPS Medical Breakthroughs ETF (SBIO) for Q3 2021, worth a combined $71.7M — down 4.2% from $74.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SBIO and 7 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was Phoenix Financial, adding an estimated $2.84M. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.54M.
- 60 institutional investors held ALPS Medical Breakthroughs ETF (SBIO) as of Q3 2021, down from 66 in Q2 2021.
- Funds reported $71.7M of ALPS Medical Breakthroughs ETF stock for Q3 2021, down 4.2% quarter-over-quarter.
- 7 funds opened new ALPS Medical Breakthroughs ETF positions in Q3 2021 and 10 closed out, a net change of -3 holders.
- The largest ALPS Medical Breakthroughs ETF buyer in Q3 2021 was Phoenix Financial, an estimated $2.84M added.
- The largest ALPS Medical Breakthroughs ETF seller in Q3 2021 was Tower Research Capital (TRC), an estimated $1.54M sold.
Based on aggregated 13F filings for Q3 2021.